XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaborative Arrangements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized financial information related to this collaboration is as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
($ in millions) | 2020 |  | 2019 |  | 2020 |  | 2019
Alliance revenue - Lynparza | $ | 178 |  |  | $ | 111 |  |  | $ | 323 |  |  | $ | 190 |
Cost of sales (1) | 137 |  |  | 73 |  |  | 164 |  |  | 92 |
Selling, general and administrative | 39 |  |  | 33 |  |  | 72 |  |  | 59 |
Research and development | 37 |  |  | 33 |  |  | 73 |  |  | 78 |
($ in millions) |  |  |  |  | June 30, 2020 |  | December 31, 2019
Receivables from AstraZeneca included in Other current assets |  |  |  |  | $ | 168 |  |  | $ | 128 |
Payables to AstraZeneca included in Accrued and other current liabilities (2) |  |  |  |  | 324 |  |  | 577 |
Payables to AstraZeneca included in Other Noncurrent Liabilities (2) |  |  |  |  | 400 |  |  | — |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
($ in millions) | 2020 |  | 2019 |  | 2020 |  | 2019
Alliance revenue - Adempas | $ | 79 |  |  | $ | 51 |  |  | $ | 133 |  |  | $ | 94 |
Net sales of Adempas recorded by Merck | 57 |  |  | 53 |  |  | 113 |  |  | 100 |
Total sales | $ | 136 |  |  | $ | 104 |  |  | $ | 246 |  |  | $ | 194 |
Cost of sales (1) | 28 |  |  | 29 |  |  | 57 |  |  | 58 |
Selling, general and administrative | 17 |  |  | 11 |  |  | 28 |  |  | 20 |
Research and development | 16 |  |  | 32 |  |  | 41 |  |  | 62 |
($ in millions) |  |  |  |  | June 30, 2020 |  | December 31, 2019
Receivables from Bayer included in Other current assets |  |  |  |  | $ | 62 |  |  | $ | 49 |
Payables to Bayer included in Other Noncurrent Liabilities (2) |  |  |  |  | 375 |  |  | 375 |
(1) Includes amortization of intangible assets. (2) Represents accrued milestone payment. Summarized financial information related to this collaboration is as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
($ in millions) | 2020 |  | 2019 |  | 2020 |  | 2019
Alliance revenue - Lenvima | $ | 151 |  |  | $ | 97 |  |  | $ | 279 |  |  | $ | 171 |
Cost of sales (1) | 135 |  |  | 23 |  |  | 170 |  |  | 74 |
Selling, general and administrative | 19 |  |  | 19 |  |  | 31 |  |  | 38 |
Research and development | 56 |  |  | 62 |  |  | 120 |  |  | 109 |
($ in millions) |  |  |  |  | June 30, 2020 |  | December 31, 2019
Receivables from Eisai included in Other current assets |  |  |  |  | $ | 173 |  |  | $ | 150 |
Payables to Eisai included in Accrued and other current liabilities (2) |  |  |  |  | 325 |  |  | 700 |
Payables to Eisai included in Other Noncurrent Liabilities (3) |  |  |  |  | 570 |  |  | 525 |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone and future option payments. (3) Includes accrued milestone payments.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration